55. Dai NT, Chen TM, Cheng TY, et al. The comparison of early fluid therapy in extensive flame burns
between inhalation and noninhalation injuries. Burns 1998;24:671–675.
56. Schiller WR, Bay RC. Hemodynamic and oxygen transport monitoring in management of burns.
New Horiz 1996;4:475–482.
57. Lorente JA, Ezpeleta A, Esteban A, et al. Systemic hemodynamics, gastric intramucosal PCO2
changes, and outcome in critically ill burn patients. Crit Care Med 2000;28:1728–1735.
58. Holm C, Melcer B, Horbrand F, et al. Haemodynamic and oxygen transport responses in survivors
and non-survivors following thermal injury. Burns 2000;26:25–33.
59. Kashefi NS, Nathan JI, Dissanaike S. Does a nebulized heparin/N-acetylcysteine protocol improve
outcomes in adult smoke inhalation? Plast Reconstr Surg Glob Open 2014;2:e165.
60. Miller AC, Rivero A, Ziad S, et al. Influence of nebulized unfractionated heparin and Nacetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009;30:249–256.
61. Palmieri TL, Enkhbaatar P, Bayliss R, et al. Continuous nebulized albuterol attenuates acute lung
injury in an ovine model of combined burn and smoke inhalation. Crit Care Med 2006;34:1719–
1724.
62. Salman D, Finney SJ, Griffiths MJ. Strategies to reduce ventilator-associated lung injury (VALI).
Burns 2013;39:200–211.
63. Peck MD, Koppelman T. Low-tidal-volume ventilation as a strategy to reduce ventilator-associated
injury in ALI and ARDS. J Burn Care Res 2009;30:172–175.
64. Chung KK, Wolf SE, Renz EM, et al. High-frequency percussive ventilation and low tidal volume
ventilation in burns: a randomized controlled trial. Crit Care Med 2010;38:1970–1977.
65. Mosier MJ, Pham TN. American Burn Association Practice guidelines for prevention, diagnosis, and
treatment of ventilator-associated pneumonia (VAP) in burn patients. J Burn Care Res 2009;30:910–
928.
66. Herndon DN, Barrow RE, Stein M, et al. Increased mortality with intravenous supplemental feeding
in severely burned patients. J Burn Care Rehabil 1989;10:309–313.
67. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns.
N Engl J Med 2001;345:1223–1229.
68. Hemmila MR, Taddonio MA, Arbabi S, et al. Intensive insulin therapy is associated with reduced
infectious complications in burn patients. Surgery 2008;144(4):629–635.
69. Atiyeh BS, Costagliola M, Hayek SN, et al. Review effect of silver on burn wound infection control
and healing: review of the literature. Burns 2007;33:139–148.
70. Falcone PA, Harrison HN, Sowemimo GO, et al. Mafenide acetate concentrations and bacteriostasis
in experimental burn wounds treated with a three-layered laminated mafenide-saline dressing. Ann
Plast Surg 1980;5:226–229.
71. Fong J, Wood F. Nanocrystalline silver dressings in wound management: a review. Nanomedicine
2006;1:441–449.
72. Gravante G, Caruso R, Sorge R, et al. Nanocrystalline silver: a systematic review of randomized
trials conducted on burned patients and an evidence-based assessment of potential advantages over
older silver formulations. Ann Plast Surg 2009;63:201–205.
406
http://surgerybook.net/
73. Engav L, Hiembach D, Reus J, et al. Early excision and grafting vs. nonoperative treatment of burns
of indeterminant depth: a randomized prospective study. J Trauma 1983;23:510–517.
74. Gray D, Pine R, Harnar T, et al. Early surgical excision versus conventional therapy in patients with
20 to 40 percent burns. A comparative study. Am J Surg 1982;144:76–80.
75. Mulholland MW. Greenfield’s Surgery. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
76. Sterling J, Gibran NS, Klein MB. Acute management of hand burns. Hand Clin 2009;25:453–459.
77. Klein MB, Moore ML, Costa B, et al. Primer on the management of face burns at the University of
Washington. J Burn Care Res 2005;26:2–6.
78. Benichou G, Yamada Y, Yun SH, et al. Immune recognition and rejection of allogeneic skin grafts.
Immunotherapy 2011;3:757–770.
79. Ronfard V, Rives JM, Neveux Y, et al. Long-term regeneration of human epidermis on third degree
burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation
2000;70:1588–1598.
80. Atiyeh BS. Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns
2007;33:405–413.
81. Elliott M, Vandervord J. Initial experience with cultured epithelial autografts in massively burnt
patients. ANZ J Surg 2002;72:893–895.
82. Paddle-Ledinek JE, Cruickshank DG, Masterton JP. Skin replacement by cultured keratinocyte
grafts: an Australia experience. Burns 1997;23:204–211.
83. Brown D, Borschel GH. Michigan Manual of Plastic Surgery. Philadelphia, PA: Lippincott Williams &
Wilkins; 2004.
84. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheterrelated infections. Healthcare Infection Control Practices Advisory Committee. Am J Infect Control
2011;39(4 suppl 1):S1–34. doi:10.1016/j.ajic.2011.01.003
85. Tandara AA, Mustoe TA. The role of the epidermis in the control of scarring: evidence for
mechanism of action for silicone gel. J Plast Reconstr Aesthet Surg 2008;61:1219–1225.
86. Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic
Plast Surg 2008;32:82–92.
87. Saulis AS, Chao JD, Telser A, et al. Silicone occlusive treatment of hypertrophic scar in the rabbit
model. Aesthet Surg J 2002;22:147–153.
88. Steinstraesser L, Flak E, Witte B, et al. Pressure garment therapy alone and in combination with
silicone for the prevention of hypertrophic scarring: randomized controlled trial with
intraindividual comparison. Plast Reconstr Surg 2011;128:306e–313e.
89. Van den Kerckhove E, Stappaerts K, Fieuws S, et al. The assessment of erythema and thickness on
burn related scars during pressure garment therapy as a preventive measure for hypertrophic
scarring. Burns 2005;31:696–702.
90. Lawrence JW, Mason ST, Schomer K, et al. Epidemiology and impact of scarring after burn injury:
a systematic review of the literature. J Burn Care Res 2012;33:136–146.
91. Gangemi EN, Gregori D, Berchialla P, et al. Epidemiology and risk factors for pathologic scarring
after burn wounds. Arch Facial Plast Surg 2008;10:93–102.
92. Nedelec B, Shankowsky H, Scott PG, et al. Myofibroblasts and apoptosis in human hypertrophic
scars: the effect of interferon-alpha2b. Surgery 2001; 130:798–808.
93. Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment.
Wound Repair Regen 2007;15:S6–S17.
94. Longacre JJ, Berry HK, Basom CR, et al. The effects of Z plasty on hypertrophic scars. Scand J Plast
Reconstr Surg 1976;10:113–128.
95. Davis JS. The relaxation of scar contractures by means of the Z-, or reversed Z-type incision:
stressing the use of scar infiltrated tissues. Ann Surg 1931;94:871–884.
96. Parnell LK, Nedelec B, Rachelska G, et al. Assessment of pruritus characteristics and impact on burn
survivors. J Burn Care Res 2012;33:407–418.
97. Klinger M, Marazzi M, Vigo D. Fat injection for cases of severe burn outcomes: a new perspective
of scar remodeling and reduction. Aesthetic Plast Surg 2008;32:465–469.
98. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg 2008;206:719–
407
http://surgerybook.net/
730.
99. Zouboulis CC, Blume U, Buttner P, et al. Outcomes of cryosurgery in keloids and hypertrophic
scars. A prospective consecutive trial of case series. Arch Dermatol 1993;129:1146–1151.
100. Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae. Semin Cutan Med
Surg 2000;19:287–292.
101. Manuskiatti W, Wanitphakdeedecha R, Fitzpatrick RE. Effect of pulse width of a 595-nm flashlamppumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars.
Dermatol Surg 2007;33:152–161.
102. Manuskiatti W, Fitzpatrick RE, Goldman MP. Energy density and numbers of treatment affect
response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulseddye laser. J Am Acad Dermatol 2001;45:557–565.
103. Garden JM, Tan OT, Kerschmann R, et al. Effect of dye laser pulse duration on selective cutaneous
vascular injury. J Invest Dermatol 1986;87:653–657.
104. Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis: a new concept for cutaneous
remodeling using microscopic patterns of thermal injury. Laser Surg Med 2004;34:426–438.
105. Gore DC, Chinkes DL, Wolf SE, et al. Quantification of protein metabolism in vivo for skin, wound,
and muscle in severe burn patients. JPEN J Parenter Enteral Nutr 2006;30:331–338.
106. Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistance of the pathophysiologic response
to severe burn injury. PLoS One 2011;6:e21245.
107. Rutan RL, Herndon DN. Growth delay in postburn pediatric patients. Arch Surg 1990;125:392–395.
108. Tuvdendorj D, Chinkes DL, Zhang XJ, et al. Skeletal muscle is anabolically unresponsive to an
amino acid infusion in pediatric burn patients 6 months postinjury. Ann Surg 2011;253:592–597.
109. Porter C, Cotter M, Diaz EC, et al. Amino acid infusion fails to stimulate skeletal muscle protein
synthesis up to 1 year after injury in children with severe burns. J Trauma Acute Care Surg
2013;74:1480–1485.
110. Padfield KE, Astrakas LG, Zhang Q, et al. Burn injury causes mitochondrial dysfunction in skeletal
muscle. Proc Natl Acad Sci U S A 2005;102:5368–5373.
111. Righi V, Constantinou C, Mintzopoulos D, et al. Mitochondria-targeted antioxidant promotes
recovery of skeletal muscle mitochondrial function after burn trauma assessed by in vivo 31P
nuclear magnetic resonance and electron paramagnetic resonance spectroscopy. FASEB J
2013;27:2521–2530.
112. Cree MG, Zwetsloot JJ, Herndon DN, et al. Insulin sensitivity and mitochondrial function are
improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg
2007;245:214–221.
113. Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and
function in children with severe burns. Pediatrics 2007;119:e109–e116.
114. Elledge ES, Smith AA, McManus WF, et al. Heterotopic bone formation in burned patients. J
Trauma 1988;28:684–687.
115. Esselman PC, Thombs BD, Magyar-Russell G, et al. Burn rehabilitation: state of the science. Am J
Phys Med Rehabil 2006;85:383–413.
116. Evans EB. Orthopaedic measures in the treatment of severe burns. J Bone Joint Surg Am
1966;48:643–669.
117. Klein MB, Logsetty S, Costa B, et al. Extended time to wound closure is associated with increased
risk of heterotopic ossification of the elbow. J Burn Care Res 2007;28:447–450.
118. Maender C, Sahajpal D, Wright TW. Treatment of heterotopic ossification of the elbow following
burn injury: recommendations for surgical excision and perioperative prophylaxis using radiation
therapy. J Shoulder Elbow Surg 2010;19:1269–1275.
119. Orzel J, Rudd T. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl
Med 1985;26:125–132.
120. Neal B, Rogers A, Clark T, et al. A systematic survey of 13 randomized trials of non-steroidal antiinflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta
Orthop Scand 2000;71:122–128.
121. Fearonce G, Faraklas I, Saffle J, et al. Peripherally inserted central venous catheters and central
venous catheters in burn patients: a comparative review. J Burn Care Res 2010;31:31–35.
408
No comments:
Post a Comment
اكتب تعليق حول الموضوع